{
  "actions": [
    {
      "acted_at": "2019-12-11",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2019-12-11",
      "action_code": "H11100",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2019-12-11",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.",
      "type": "referral"
    },
    {
      "acted_at": "2019-12-12",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr5402-116",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM"
    }
  ],
  "congress": "116",
  "cosponsors": [
    {
      "bioguide_id": "F000466",
      "district": "1",
      "name": "Fitzpatrick, Brian K.",
      "original_cosponsor": false,
      "sponsored_at": "2019-12-18",
      "state": "PA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "U000031",
      "district": "6",
      "name": "Upton, Fred",
      "original_cosponsor": true,
      "sponsored_at": "2019-12-11",
      "state": "MI",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2019-12-11",
  "number": "5402",
  "official_title": "To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to conduct a study on high-risk, high-reward drugs, and for other purposes.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Protecting America\u00e2\u20ac\u2122s Life Saving Medicines Act of 2019",
  "sponsor": {
    "bioguide_id": "G000583",
    "district": "5",
    "name": "Gottheimer, Josh",
    "state": "NJ",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2019-12-11",
  "subjects": [
    "Drug safety, medical device, and laboratory regulation",
    "Drug therapy",
    "Government studies and investigations",
    "Income tax credits",
    "Medical research",
    "Taxation"
  ],
  "subjects_top_term": "Taxation",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2019-12-11",
    "date": "2020-01-07T16:52:19Z",
    "text": "Protecting America's Life Saving Medicines Act of 2019\n\nThis bill directs the Food and Drug Administration (FDA) to conduct a study on drugs that are currently being tested and are unlikely to be approved, but would, if approved, address an unmet medical need for the treatment of a serious or life threatening disease or condition or a rare disease or condition (high-risk, high-reward drugs). The FDA must submit to the Department of the Treasury a list of such high-risk, high-reward drugs not later than 180 days after the completion of the study.\n\nThe bill also allows a new tax credit for 25% of the clinical testing expenses for high-risk, high-reward drugs."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Protecting America\u00e2\u20ac\u2122s Life Saving Medicines Act of 2019",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to conduct a study on high-risk, high-reward drugs, and for other purposes.",
      "type": "official"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Protecting America\u00e2\u20ac\u2122s Life Saving Medicines Act of 2019",
      "type": "short"
    }
  ],
  "updated_at": "2022-10-28T01:45:59Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/hr/BILLSTATUS-116hr5402.xml"
}